Ziarco Initiates Phase 2a Clinical Trial of ZPL-389 in Atopic Dermatitis – GlobeNewswire (press release)

Ziarco Initiates Phase 2a Clinical Trial of ZPL-389 in Atopic DermatitisGlobeNewswire (press release)"Our oral H4 receptor antagonist has the potential to improve the quality of life for patients with inflammatory skin conditions such as atopic dermatitis by providing them with a safe, effective and convenient treatment. Data from this trial are …and more »

[monetize id=”1″]
[monetize id=”2″]

Atopic Dermatitis in Infants – An Overview on What is Eczema

Pfizer Announces 12 Presentations Including New Research Data on Tofacitinib … – MarketWatch

European Pharmaceutical ReviewPfizer Announces 12 Presentations Including New Research Data on Tofacitinib …MarketWatchIn addition, new Phase 2a data for topical tofacitinib in the treatment of atopic dermatitis will be presented for the first time. “We are proud of the data from the tofacitinib psoriasis clinical development program being presented at WCD as it adds …News Buzz – Pfizer (PFE), Verizon (VZ), AT&T (T), Bank (BAC)Investor Wiredall 17 news articles »

https://www.dpsw.org/eczema-atopic-dermat…